JP2015502346A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015502346A5 JP2015502346A5 JP2014541386A JP2014541386A JP2015502346A5 JP 2015502346 A5 JP2015502346 A5 JP 2015502346A5 JP 2014541386 A JP2014541386 A JP 2014541386A JP 2014541386 A JP2014541386 A JP 2014541386A JP 2015502346 A5 JP2015502346 A5 JP 2015502346A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- item
- disorder
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 230000002092 calcimimetic effect Effects 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 208000037157 Azotemia Diseases 0.000 claims description 2
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 208000025061 parathyroid hyperplasia Diseases 0.000 claims description 2
- 230000002037 soft tissue calcification Effects 0.000 claims description 2
- 208000009852 uremia Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 125000002091 cationic group Chemical group 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558389P | 2011-11-10 | 2011-11-10 | |
| US61/558,389 | 2011-11-10 | ||
| PCT/US2012/064717 WO2013071262A1 (en) | 2011-11-10 | 2012-11-12 | Calcimimetics and methods for their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017123032A Division JP2017160269A (ja) | 2011-11-10 | 2017-06-23 | カルシウム模倣薬およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015502346A JP2015502346A (ja) | 2015-01-22 |
| JP2015502346A5 true JP2015502346A5 (enExample) | 2016-01-07 |
| JP6204369B2 JP6204369B2 (ja) | 2017-09-27 |
Family
ID=47258113
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541386A Active JP6204369B2 (ja) | 2011-11-10 | 2012-11-12 | カルシウム模倣薬およびその使用方法 |
| JP2017123032A Withdrawn JP2017160269A (ja) | 2011-11-10 | 2017-06-23 | カルシウム模倣薬およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017123032A Withdrawn JP2017160269A (ja) | 2011-11-10 | 2017-06-23 | カルシウム模倣薬およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20140315809A1 (enExample) |
| EP (1) | EP2776129B2 (enExample) |
| JP (2) | JP6204369B2 (enExample) |
| CN (2) | CN109985228A (enExample) |
| AU (1) | AU2012335009B2 (enExample) |
| CA (1) | CA2854911C (enExample) |
| HK (1) | HK1202086A1 (enExample) |
| MX (1) | MX355063B (enExample) |
| WO (1) | WO2013071262A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4874954B2 (ja) | 2004-04-21 | 2012-02-15 | エノビア ファーマ インコーポレイティド | 骨送達複合体ならびにタンパク質に骨を標的化させるためのその使用方法 |
| CN107674114B (zh) | 2009-07-29 | 2022-10-25 | 凯伊药品公司 | 用于降低甲状旁腺激素水平的治疗剂 |
| PL3013318T3 (pl) | 2013-06-28 | 2018-03-30 | Amgen Inc. | Stabilny ciekły preparat związku amg 416 (welkalcetyd) |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| US20170304228A1 (en) * | 2014-10-24 | 2017-10-26 | Launx Biomedical Co., Ltd. | New indication of cinacalcet hcl pharmaceutical composition for treating cancer |
| ES3038086T3 (en) | 2014-12-05 | 2025-10-09 | Alexion Pharma Inc | Treating seizure with recombinant alkaline phosphatase |
| US9539264B2 (en) * | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
| EP3250227A2 (en) * | 2015-01-28 | 2017-12-06 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| KR102644116B1 (ko) | 2015-08-17 | 2024-03-05 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼린 포스파타제의 제조 |
| US11229686B2 (en) | 2015-09-28 | 2022-01-25 | Alexion Pharmaceuticals, Inc. | Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia |
| EP3368062A4 (en) | 2015-10-30 | 2019-07-03 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT |
| CN106928320B (zh) | 2015-12-31 | 2021-01-15 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS |
| JP7613826B2 (ja) | 2016-04-01 | 2025-01-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| KR20240158374A (ko) | 2017-03-31 | 2024-11-04 | 알렉시온 파마슈티칼스, 인코포레이티드 | 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법 |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| EP3867650A1 (en) * | 2018-10-18 | 2021-08-25 | Fresenius Medical Care Holdings, Inc. | Techniques for modeling parathyroid gland functionality and calcimimetic drug activity |
| JP7796013B2 (ja) * | 2019-12-09 | 2026-01-08 | 北京拓界生物医薬科技有限公司 | カルシウム感知受容体アゴニスト化合物及びその使用 |
| AU2020398898A1 (en) | 2019-12-09 | 2022-07-21 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| US20230331779A1 (en) * | 2020-09-10 | 2023-10-19 | Shaanxi Micot Technology Co., Ltd. | Bispecific fusion polypeptide compound |
| BR112023016048A2 (pt) | 2021-02-12 | 2023-11-14 | Alexion Pharma Inc | Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos |
| CN117500820A (zh) * | 2021-06-08 | 2024-02-02 | 北京拓界生物医药科技有限公司 | 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用 |
| US20240269227A1 (en) * | 2021-06-08 | 2024-08-15 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Calcium-sensing receptor agonist composition and application thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| US5869473A (en) | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US5246925A (en) | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
| CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| EP0917537B1 (en) * | 1996-07-31 | 2005-09-07 | The General Hospital Corporation | Novel parathyroid hormone-related peptide analogs |
| US6051567A (en) | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
| US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
| AU2001278956B2 (en) | 2000-07-18 | 2007-04-05 | Genzyme Corporation | Stabilized 1alpha-hydroxy vitamin d |
| US6998404B2 (en) * | 2001-08-08 | 2006-02-14 | Genomed, Llc | Treatment or prevention of acute renal failure |
| BRPI0609524A2 (pt) * | 2005-03-17 | 2011-10-18 | Amgen Inc | uso de uma quantidade terapeuticamente eficaz de um composto calcimimético |
| JP5645408B2 (ja) | 2006-11-16 | 2014-12-24 | カイ ファーマシューティカルズ インコーポレーティッド | 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド |
| CA2701638A1 (en) * | 2007-04-02 | 2008-10-09 | Concert Pharmaceuticals Inc. | Pharmaceutical calcimimetics |
| CN107674114B (zh) * | 2009-07-29 | 2022-10-25 | 凯伊药品公司 | 用于降低甲状旁腺激素水平的治疗剂 |
| GB0913525D0 (en) * | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
-
2012
- 2012-11-12 CN CN201910103503.4A patent/CN109985228A/zh active Pending
- 2012-11-12 AU AU2012335009A patent/AU2012335009B2/en active Active
- 2012-11-12 JP JP2014541386A patent/JP6204369B2/ja active Active
- 2012-11-12 CA CA2854911A patent/CA2854911C/en active Active
- 2012-11-12 US US14/357,702 patent/US20140315809A1/en not_active Abandoned
- 2012-11-12 EP EP12791926.4A patent/EP2776129B2/en active Active
- 2012-11-12 HK HK15102648.5A patent/HK1202086A1/xx unknown
- 2012-11-12 CN CN201280066707.1A patent/CN104168955A/zh active Pending
- 2012-11-12 MX MX2014005662A patent/MX355063B/es active IP Right Grant
- 2012-11-12 WO PCT/US2012/064717 patent/WO2013071262A1/en not_active Ceased
-
2016
- 2016-03-01 US US15/057,742 patent/US20160175383A1/en not_active Abandoned
-
2017
- 2017-05-23 US US15/603,279 patent/US20170252397A1/en not_active Abandoned
- 2017-06-23 JP JP2017123032A patent/JP2017160269A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015502346A5 (enExample) | ||
| JP2015522576A5 (enExample) | ||
| MX2011012131A (es) | Perhexilina para usarla en el tratamiento de miocardiopatía hipertrófica (hcm). | |
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| JP2013518815A5 (enExample) | ||
| JP2010202664A5 (enExample) | ||
| NO20101036L (no) | Behandle og profylakse av amyloidose | |
| JP2012115277A5 (enExample) | ||
| JP2013539454A5 (enExample) | ||
| JP2013520405A5 (enExample) | ||
| RU2015120804A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
| JP2011105739A5 (enExample) | ||
| JP2014051497A5 (enExample) | ||
| JP2012136541A5 (enExample) | ||
| EA201490809A1 (ru) | Способы и композиции для лечения неэффективного эритропоэза | |
| JP2016504275A5 (enExample) | ||
| JP2013503110A5 (enExample) | ||
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| WO2012159052A3 (en) | Targeted delivery of proteins across the blood brain barrier | |
| JP2017511377A5 (enExample) | ||
| JP2012513193A5 (enExample) | ||
| EP3276004A3 (en) | Methods for treating chronic kidney disease | |
| MX354535B (es) | TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß. | |
| IN2015DN00528A (enExample) | ||
| JP2016512817A5 (enExample) |